Blood online
Home About Blood Authors Subscriptions Permission Advertising Public Access contact us
 

 
Advanced
Current Issue
First Edition
Future Articles
Archives
Submit to Blood
Search
American Society of Hematology
Meeting Abstracts
Email Alerts
Blood, 15 February 2007, Vol. 109, No. 4, pp. 1414-1421.
Prepublished online as a Blood First Edition Paper on November 7, 2006; DOI 10.1182/blood-2006-03-010181.


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
blood-2006-03-010181v1
109/4/1414    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Right arrow Rights and Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Nathwani, A. C.
Right arrow Articles by Davidoff, A. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Nathwani, A. C.
Right arrow Articles by Davidoff, A. M.
Related Collections
Right arrow Hemostasis, Thrombosis, and Vascular Biology
Right arrow Gene Therapy
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

arrow to previous article Previous Article  |  Table of Contents  |  Next Article next article arrow

GENE THERAPY

Safe and efficient transduction of the liver after peripheral vein infusion of self-complementary AAV vector results in stable therapeutic expression of human FIX in nonhuman primates

Amit C. Nathwani1,2, John T. Gray3, Jenny McIntosh1, Catherine Y. C. Ng4, Junfang Zhou4, Yunyu Spence4, Melanie Cochrane1, Elaine Gray5, Edward G. D. Tuddenham1,6, and Andrew M. Davidoff3,4

1 Department of Haematology, University College London and 2 National Blood Service, United Kingdom; 3 Division of Experimental Hematology and 4 Department of Surgery, St Jude Children's Research Hospital, Memphis, TN; 5 Department of Haematology, National Institute for Biological Standards and Control, Potters Bar, United Kingdom; and 6 Katharine Dormandy Haemophilia Centre, London, United Kingdom

The safety and efficacy of peripheral venous administration of a self-complementary adeno-associated viral vector encoding the human FIX gene (scAAV-LP1-hFIXco) was evaluated in nonhuman primates for gene therapy of hemophilia B. Peripheral vein infusion of 1 x 1012 vg/kg scAAV-LP1-hFIXco pseudotyped with serotype 8 capsid, in 3 macaques, resulted in stable therapeutic expression (more than 9 months) of human FIX (hFIX) at levels (1.1 ± 0.5 µg/mL, or 22% of normal) that were comparable to those achieved after direct delivery of the same vector dose into the portal circulation (1.3 ± 0.3 µg/mL, or 26% of normal). Importantly, the pattern of vector biodistribution after systemic and portal vein administration of scAAV-LP1-hFIXco was almost identical. Additionally, comparable levels of gene transfer were achieved in macaques with preexisting immunity to AAV8 following peripheral vein administration of 1 x 1012 vg/kg AAV5-pseudotyped scAAV-LP1-hFIXco. This confirms that alternative serotypes can circumvent preexisting naturally acquired immunity to AAV. Thus, peripheral venous administration of AAV5 and AAV8 vectors is safe and as effective at transducing the liver in nonhuman primates as direct vector administration into the portal circulation. These results should make vector administration to patients, especially those with a severe bleeding diathesis, significantly easier and safer.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Hum Mol GenetHome page
M. H. Tan, A. J. Smith, B. Pawlyk, X. Xu, X. Liu, J. B. Bainbridge, M. Basche, J. McIntosh, H. V. Tran, A. Nathwani, et al.
Gene therapy for retinitis pigmentosa and Leber congenital amaurosis caused by defects in AIPL1: effective rescue of mouse models of partial and complete Aipl1 deficiency using AAV2/2 and AAV2/8 vectors
Hum. Mol. Genet., June 15, 2009; 18(12): 2099 - 2114.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
F. Mingozzi, N. C. Hasbrouck, E. Basner-Tschakarjan, S. A. Edmonson, D. J. Hui, D. E. Sabatino, S. Zhou, J. F. Wright, H. Jiang, G. F. Pierce, et al.
Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver
Blood, October 1, 2007; 110(7): 2334 - 2341.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
T. Ito, T. Okada, J. Mimuro, H. Miyashita, R. Uchibori, M. Urabe, H. Mizukami, A. Kume, M. Takahashi, U. Ikeda, et al.
Adenoassociated Virus Mediated Prostacyclin Synthase Expression Prevents Pulmonary Arterial Hypertension in Rats
Hypertension, September 1, 2007; 50(3): 531 - 536.
[Abstract] [Full Text] [PDF]


Home page
ASH Education BookHome page
K. A. High
Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia
Hematology, January 1, 2007; 2007(1): 466 - 472.
[Abstract] [Full Text] [PDF]



 click for free articles
home about blood authors subscriptions permissions advertising public access contact us
  Copyright © 2007 by American Society of Hematology         Online ISSN: 1528-0020